Which vaccines are effective in the prevention of invasive pneumococcal disease?

Updated: Sep 30, 2020
  • Author: Justina Gamache, MD; Chief Editor: Guy W Soo Hoo, MD, MPH  more...
  • Print

A 23-valent capsular polysaccharide vaccine (Pneumovax 23) and a 13-valent protein-polysaccharide conjugate vaccine (Prevnar 13) are currently available in the United States. Both vaccines are efficacious in the prevention of invasive pneumococcal disease. The role of the pneumococcal vaccine has not been defined as clearly as that of the influenza vaccine in adults. Pneumococcal 13-valent conjugate vaccine is approved for children aged six weeks to five years and adults aged 50 years or older. The pneumococcal 23-valent vaccine is approved for adults aged 50 years or older and persons aged two years or older who are at increased risk for pneumococcal disease.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!